Xiangqing Xu

NHWA Institute of Pharmaceutical Research

H指数:18

被引数:837

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neuropsychiatric drug development in China: Current status and emerging trends

中国神经精神药物研发：现状与新兴趋势

Molecular Psychiatry

IF10.1

2026-02-060

PRE

The Microbiota-gut-brain axis in vascular cognitive impairment: unraveling the mysterious link and therapeutic prospects

血管性认知障碍中的微生物-肠道-大脑轴：揭示神秘联系与治疗前景

Frontiers in Immunology

IF5.9

2025-10-070

OAAI

Cognitive impairment assessment using eye-tracking: multilevel saccade paradigms with differential analysis and attention-based neural networks

眼动追踪认知障碍评估：多层次扫视范式与差异分析及基于注意力的神经网络

PHYSIOLOGICAL MEASUREMENT

IF2.7

2025-09-300

PRE

Paeoniflorin as a Potential Therapeutic Agent for Cerebrovascular Diseases: A Comprehensive Review

芍药苷作为脑血管疾病潜在治疗药物：一项综合性综述

Pharmacological Research

IF10.5

2025-09-190

OAAI

Design, Synthesis, and Pharmacological Evaluation of Novel M4 Muscarinic Receptor Positive Allosteric Modulators for Schizophrenia Treatment

M4毒蕈碱型受体正向别构调节剂的分子设计、合成及其药理学评价——用于精神分裂症治疗

European Journal of Medicinal Chemistry

IF5.9

2025-07-250

PRE

Investigation of long-range plasmonic field effects in Au@SiO2 nanostructures using p-nitrophenol reduction

JOURNAL OF ALLOYS AND COMPOUNDS

IF6.3

2025-01-010

PRE

Amphetamine Derivatives as Potent Central Nervous System Multitarget SERT/NET/H3 Agents: Synthesis and Biological Evaluation

MOLECULES

IF4.6

2024-11-060

OAAI

Hybrid-feature based spherical quasi-conformal registration for AD-induced hippocampal surface morphological changes

COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

IF4.8

2024-11-010

OAAI

Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2024-11-010

PRE

A novel dual serotonin transporter and M-channel inhibitor D01 for antidepression and cognitive improvement

ACTA PHARMACEUTICA SINICA B

IF14.6

2024-03-011

OAAI

The role of CD38 in inflammation-induced depression-like behavior and the antidepressant effect of (R)-ketamine

BRAIN BEHAVIOR AND IMMUNITY

IF7.6

2024-01-0113

PRE

Carbazole and tetrahydro-carboline derivatives as dopamine D3 receptor antagonists with the multiple antipsychotic-like properties

咔唑和四氢咔啉衍生物作为具有多种抗精神病特性的多巴胺D3受体拮抗剂

ACTA PHARMACEUTICA SINICA B

IF14.6

2023-11-011

OAAI

Myelin-associated oligodendrocytic basic protein-dependent myelin repair confers the long-lasting antidepressant effect of ketamine

MOLECULAR PSYCHIATRY

IF10.1

2023-10-1713

PRE

Tongmai Zhuke decoction restrains the inflammatory reaction of macrophages for carotid artery atherosclerosis by up-regulating lincRNA-Cox2

BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS

IF1.9

2023-04-044

PRE

A Novel Etomidate Analog EL-0052 Retains Potent Hypnotic Effect and Stable Hemodynamics without Suppressing Adrenocortical Function

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2021-12-013

OAAI

The Calcium Channel α2δ1 Subunit: Interactional Targets in Primary Sensory Neurons and Role in Neuropathic Pain

FRONTIERS IN CELLULAR NEUROSCIENCE

IF4

2021-09-3015

OAAI

Discovery of 4-arylthiophene-3-carboxylic acid as inhibitor of ANO1 and its effect as analgesic agent

ACTA PHARMACEUTICA SINICA B

IF14.6

2021-07-0115

OAAI

Discovery of Novel and Potent N-Methyl-D-aspartate Receptor Positive Allosteric Modulators with Antidepressant-like Activity in Rodent Models

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-05-0314

PREAI

Synthesis and Biological Evaluation of Fused Tricyclic Heterocycle Piperazine (Piperidine) Derivatives As Potential Multireceptor Atypical Antipsychotics

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2018-11-0146

PREAI

Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

IF3.8

2018-06-0113

OAAI

Xiangqing Xu

个人简介

教育背景

工作经历

荣誉奖项

研究方向